1 / 10

Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4

This slide deck provides an overview of the Phase 3 HIV Coinfection Treatment with Ledipasvir-Sofosbuvir in GT1 or GT4, including study design, drug dosing, baseline characteristics, antiretroviral regimens, results, adverse effects, and conclusions.

lawrencejohnson
Download Presentation

Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 HIV Coinfection Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV CoinfectionION-4 Naggie S, et al. N Engl J Med 2015;378:705-13.

  2. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Features Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  3. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Study Design 0 12 24 Week GT 1 or 4N = 335 Ledipasvir- Sofosbuvir SVR12 Drug Dosing: Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyAntiretrovirals allowed: tenofovir-emtricitabineplus either efavirenz, rilpivirine, or raltegravir Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  4. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Baseline Characteristics Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  5. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Antiretroviral Regimens Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  6. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Results ION-4: SVR12 Results by Genotype 321/335 240/250 74/77 8/8 Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  7. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Results ION-4: SVR12 Results by Prior Treatment Status and Liver Status 321/335 142/150 179/185 258/268 63/67 Prior Treatment Status Liver Status Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  8. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Adverse Effects Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  9. Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV CoinfectionION-4 Trial: Conclusions Source: Naggie S, et al. N Engl J Med 2015;378:705-13.

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related